Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Seong Hee Kang, Hye Won Lee, Jeong‐Ju Yoo, et al.
Clinical and Molecular Hepatology (2021) Vol. 27, Iss. 3, pp. 363-401
Open Access | Times Cited: 224

Showing 1-25 of 224 citing articles:

Global incidence and prevalence of nonalcoholic fatty liver disease
Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S32-S42
Open Access | Times Cited: 328
Non-alcoholic fatty liver disease: Definition and subtypes
Seulki Han, Soon Koo Baik, Moon Young Kim
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S5-S16
Open Access | Times Cited: 112
Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease
Youn Huh, Yoon Jeong Cho, Ga Eun Nam
Journal of Obesity & Metabolic Syndrome (2022) Vol. 31, Iss. 1, pp. 17-27
Open Access | Times Cited: 98
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD
Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 6, pp. 1482-1490
Open Access | Times Cited: 72
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Gi‐Ae Kim, Joon Ho Moon, Won Kim
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 4, pp. 831-843
Open Access | Times Cited: 72
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study
Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 433-452
Open Access | Times Cited: 43
Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease
Heejoon Jang, Yeonjin Kim, Dong Hyeon Lee, et al.
JAMA Internal Medicine (2024) Vol. 184, Iss. 4, pp. 375-375
Closed Access | Times Cited: 38
Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease
Meijing Chen, Ying Chen, Jin-qing Lin, et al.
Frontiers in Nutrition (2025) Vol. 11
Open Access | Times Cited: 2
Modelling NAFLD disease burden in four Asian regions—2019‐2030
Chris Estes, Henry Lik‐Yuen Chan, Rong‐Nan Chien, et al.
Alimentary Pharmacology & Therapeutics (2020) Vol. 51, Iss. 8, pp. 801-811
Open Access | Times Cited: 125
Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis
Stergios A. Pοlyzos, Eun Seok Kang, Chrysoula Boutari, et al.
Metabolism (2020) Vol. 111, pp. 154203-154203
Closed Access | Times Cited: 125
History of Nonalcoholic Fatty Liver Disease
Amedeo Lonardo, Simona Leoni, Khalid Alswat, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 16, pp. 5888-5888
Open Access | Times Cited: 117
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, et al.
Clinical and Molecular Hepatology (2021) Vol. 28, Iss. 2, pp. 150-163
Open Access | Times Cited: 76
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
Peter Konyn, Aijaz Ahmed, Donghee Kim
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S43-S57
Open Access | Times Cited: 57
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Naomi F. Lange, Vanessa Graf, Cyrielle Caussy, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4305-4305
Open Access | Times Cited: 54
Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study
Dong Hyun Sinn, Danbee Kang, Mira Kang, et al.
Hepatology (2022) Vol. 76, Iss. 6, pp. 1746-1754
Open Access | Times Cited: 42
Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease
Ho Soo Chun, Minjong Lee, Hye Ah Lee, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 21, Iss. 2, pp. 358-369.e12
Closed Access | Times Cited: 40
Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
Xin Ding, Xu He, Bulang Tang, et al.
Chinese Medicine (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 12
Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective
Jialan Wang, Suwen Jiang, Airong Hu, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e27325-e27325
Open Access | Times Cited: 11
Diagnostic Performance of Noninvasive Tests in Patients with MetALD in a Health Check-up Cohort
Joo Hyun Oh, Sang Bong Ahn, Seon Cho, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 9
Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis
Heejoon Jang, Yun Bin Lee, Hyemi Moon, et al.
Hepatology (2022) Vol. 76, Iss. 2, pp. 492-501
Closed Access | Times Cited: 38
Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy
Pengyu Yao, Yajuan Liu
Molecules (2022) Vol. 28, Iss. 1, pp. 272-272
Open Access | Times Cited: 36
Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role
Haripriya Gupta, Byeong-Hyun Min, Raja Ganesan, et al.
Biomedicines (2022) Vol. 10, Iss. 3, pp. 550-550
Open Access | Times Cited: 35
Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study
Chan‐Young Jung, Hee Byung Koh, Keun Hyung Park, et al.
Diabetes & Metabolism (2022) Vol. 48, Iss. 4, pp. 101344-101344
Closed Access | Times Cited: 35
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
Sara Battistella, Francesca D’Arcangelo, Marco Grasso, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S286-S301
Open Access | Times Cited: 34
Comparison between obese and non-obese nonalcoholic fatty liver disease
Wah‐Kheong Chan
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S58-S67
Open Access | Times Cited: 33
Page 1 - Next Page

Scroll to top